Skip to content
shutterstock_1313726249 shutterstock_1313726249

Gene Therapy Immunogenicity and IVD Regulatory Services

Unmatched expertise in NAb/TAb assays and in managing global regulatory engagements

Precision for Medicine provides a suite of services for adeno-associated virus (AAV) immunogenicity assays from preclinical development through gene therapeutic commercialization.

Whether your development path includes a companion diagnostic (CDx) or not, Precision experts—who are shaping and guiding this field—help determine the optimal development route for your assays, ensuring the most efficient and compliant path to market.

Proven expertise in AAV immunogenicity assays, from preclinical development through commercialization

Precision for Medicine has extensive experience with AAV immunogenicity assays for rare diseases like hemophilia, Fabry, Gaucher, muscular dystrophies, and non-rare diseases like age-related macular degeneration (AMD) and heart failure.

The assays employed encompass anti-capsid NAb and TAb, anti-transgene anti-drug antibody (ADA), and ELISpot assays targeting both anti-capsid and anti-transgene responses.

Notably, Precision for Medicine developed and serves as the lab for the single-site laboratory-developed test (LDT) anti-AAV5 NAb assay for HEMGENIX®.

25
AAV gene therapy programs supported
3
FDA-approved IDEs (+4 in progress)
40
AAV assay validations (GxP & CLIA)
175
patients tested using Precision developed commercial NAb assay for HEMGENIX®
Precision for Medicine - Gene Therapy Experience-1

Delivering NAb, TAb, and ELISpot assays for diverse capsid types at every stage

Precision for Medicine's scientific team has developed and validated NAb, TAb and ELISpot assays in both humans and non-human primates (NHPs) for several capsid types across multiple stages:

  • Preclinical/GLP
  • Clinical trial GxP
  • Clinical Trial CLIA
  • CDx
Risk assessment and regulatory requirements for CTAs

Our experienced regulatory consulting group supports AAV gene therapy assays from LDTs to IVDs and more

Precision's regulatory team provides comprehensive support at each critical step of the development timeline, from advising on requirements and design through analytical and clinical protocol development and execution. In parallel, Precision for Medicine will draft the required regulatory documentation (SRD, IDE, Annex XIV, ITA) to support clinical trials and, if needed, final commercialization (PMA, CE Mark, UKCA Mark) while communicating with the regulatory bodies to ensure compliance and streamlined review of submissions.

Purposefully integrated to support all aspects of gene therapy approvals

In addition to immunogenicity assay development and integrated regulatory consulting, Precision supports gene therapy development with a broad set of services to streamline development and avoid delays to market.

Explore our supporting gene therapy services:
cdx_case-study_gene-therapy
Case study

Precision develops and commercializes an AAV gene therapy NAb assay LDT

Precision worked with CSL Behring to develop and commercialize an LDT for their treatment for hemophilia, HEMGENIX®

  • Initial engagement with Precision for Medicine (PFM) to obtain comprehensive support in developing and commercializing a NAb assay for the vector capsid
  • Precision conducted a multi-phase support program, which included:
    • PFM labs onboarding and validating the clinical trials assay
    • PFM Regulatory shepherding the assay through the FDA
    • PFM Market Access examined commercial considerations and verified that the optimal path – direct payment to the lab for the assay by CSL Behring—is likely acceptable
    • PFM Labs and Regulatory took the necessary actions to provide the NAb assay commercially upon approval of the gene therapy

Leading the conversation: Precision’s contributions to American Association of Pharmaceutical Scientists (AAPS) Guidelines on AAV NAb, TAb, and ELISpot Assays

Experts from Precision for Medicine guide and shape the gene therapy field, actively contributing to the AAPS recommendations for the development of gene therapy NAb, TAb, and ELISpot assays. Explore our peer-reviewed articles that outline best practices in this area.

  • Research Article

    AAPS Evaluation of Cellular Immune Response to Adeno-Associated Virus Based Gene Therapy (2023)

    Download Article
    AAPS Evaluation of Cellular Immune Response to Adeno-Associated Virus Based Gene Therapy (2023)
  • Research Article

    AAPS Evaluation of the Humoral Response to Adeno-Associated Virus Based Gene Therapy Modalities Using Total Antibody Assays (2021)

    Download Article
    AAPS Evaluation of the Humoral Response to Adeno-Associated Virus Based Gene Therapy Modalities Using Total Antibody Assays (2021)
  • Research Article

    AAPS Recommendations for the Development of Cell Based Anti Viral Vector Neutralizing Antibody Assays (2020)

    Download Article
    AAPS Recommendations for the Development of Cell Based Anti Viral Vector Neutralizing Antibody Assays (2020)
PFM - Gene therapy assays_ Achieving regulatory compliance with a unified immunogenicity strategy- Webinar

Webinar

Gene Therapy Assays: Achieving Regulatory Compliance with a Unified Immunogenicity Strategy

PFM - Strategies for Immunogenicity Assays in AAV Gene Therapy_ Development to CDx Approval - Webinar_

Webinar

Strategies for Immunogenicity Assays in AAV Gene Therapy: Development to CDx Approval

PFM - NAb vs TAb Assays in Gene Therapy Development_ Key Considerations for Assessing Immunogenicity - Webinar

Webinar

NAb vs TAb Assays in Gene Therapy Development: Key Considerations for Assessing Immunogenicity

PFM - Companion Diagnostics_ Strategies for Effective Co-Development with Therapeutics - Webinar

Webinar

Companion Diagnostics: Strategies for Effective Co-development with Therapeutics

PFM_171. Optimizing Successful Development of Viral Vector Gene Therapies, Gene Therapy Trials, and Companion Diagnostics_White Paper

White paper

Optimizing Successful Development of Viral Vector Gene Therapies, Trials, and CDx

PFM-The Regulation of Companion Diagnostics-Scientific Article 2013

Research article

The Regulation of Companion Diagnostics: A Global Perspective. (2013)

Additional insights on gene therapy

Read: Gene Therapy Assays: Regulatory Compliance with Unified Immunogenicity Gene Therapy Assays: Regulatory Compliance with Unified Immunogenicity

Translational Research - Regulatory - Assays - Gene Therapies

Gene Therapy Assays: Regulatory Compliance with Unified Immunogenicity

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778875, hs_child_table_id=0, hs_updated_at=1716454216458, hs_published_at=1741014119284, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475007, name='Precision for Medicine Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1716212769184, hs_created_at=1709645745106, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job= Chief Scientific Officer, slug=deborah-phippard, email=, hs_updated_by_user_id=26433386}, second={hs_id=159488778840, hs_child_table_id=0, hs_updated_at=1716132440837, hs_published_at=1741014119284, description=Maham Ansari, MS, RAC is a Senior Director, IVD Regulatory Affairs. Her focus is on companion diagnostic co-development programs, where she leverages her regulatory expertise to secure approvals in the US, Europe and beyond for companion diagnostics with a specific focus on gene therapy. She brings more than 16 years of global regulatory leadership experience in the medical device and in vitro diagnostics industry, spanning major multinationals to small start-ups, including full life cycle management across all stages of product development, execution of global regulatory strategies, and post-market surveillance.sh, avatar=Image{width=710,height=710,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Maham_Ansari.png',altText='Maham_Ansari',fileId=167373022876}, linkedin=https://www.linkedin.com/in/maham-ansari-ms-rac-6a735739, hs_name=, hs_path=, lastname=Ansari, hs_initial_published_at=1716212769184, hs_created_at=1709645745071, hs_is_edited=false, hs_deleted_at=0, name=Maham, job=, slug=maham-ansari, email=, hs_updated_by_user_id=26433386}, third={}})
  • Deborah P. avatar

    Deborah P.

  • Maham A. avatar

    Maham A.

Read: 8 Best Practices for Immunogenicity Assay and Companion Diagnostic Development in AAV Gene Therapy Immunogenicity Assay and Companion Diagnostic Development in AAV Gene Therapy

Translational Research - Gene Therapies

8 Best Practices for Immunogenicity Assay and Companion Diagnostic Development in AAV Gene Therapy

|
    has third author: false, (SizeLimitingPyMap: {main={hs_id=159488778875, hs_child_table_id=0, hs_updated_at=1716454216458, hs_published_at=1741014119284, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475007, name='Precision for Medicine Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1716212769184, hs_created_at=1709645745106, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job= Chief Scientific Officer, slug=deborah-phippard, email=, hs_updated_by_user_id=26433386}, second={hs_id=159488778874, hs_child_table_id=0, hs_updated_at=1714461729999, hs_published_at=1741014119284, description=Kennon Daniels is a scientific and regulatory in vitro diagnostic authority, specializing in the development of US regulatory strategies and FDA marketing submissions for IVD assays and instruments. Her expertise spans all aspects of product development, analytical and clinical trial protocol designs, Q-Submissions, IDEs, de novos, 510(k)s, and pre-market approval platforms., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Kennon%20Daniels.webp',altText='Kennon Daniels',fileId=165893120790}, linkedin=https://www.linkedin.com/in/kennon-daniels-ph-d-84a90b6, hs_name=, hs_path=, lastname=Daniels, hs_initial_published_at=1716212769184, hs_created_at=1709645745105, hs_is_edited=false, hs_deleted_at=0, name=Kennon, job=, slug=kennon-daniels, email=, hs_updated_by_user_id=26433386}, third={hs_id=159488778889, hs_child_table_id=0, hs_updated_at=1714461111815, hs_published_at=1741014119284, description=Travis Harrison, PhD, is Vice President of Diagnostic Development at Precision for Medicine. He brings more than 20 years of bioanalytical assay experience to the Precision team with expertise in ligand-binding and cell-based assays.  Travis has experience supporting clinical and nonclinical studies for a broad range of indications, with an emphasis on diagnostic assays to evaluate immune responses to gene therapies., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Travis%20Harrison.webp',altText='Travis Harrison',fileId=165893006481}, linkedin=https://www.linkedin.com/in/travis-harrison-phd-6108852/, hs_name=, hs_path=, lastname=Harrison, hs_initial_published_at=1716212769184, hs_created_at=1709645745120, hs_is_edited=false, hs_deleted_at=0, name=Travis, job=, slug=travis-harrison, email=, hs_updated_by_user_id=26433386}})
  • Deborah P. avatar Kennon D. avatar Travis H. avatar
  • Deborah P.

    Kennon D.

    Travis H.

Read: Monitoring Immune Responses in Gene Therapy Clinical Trials Using ELISpot Monitoring Immune Responses in Gene Therapy Clinical Trials Using ELISpot

Translational Research - Gene Therapies

Monitoring Immune Responses in Gene Therapy Clinical Trials Using ELISpot

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778889, hs_child_table_id=0, hs_updated_at=1714461111815, hs_published_at=1741014119284, description=Travis Harrison, PhD, is Vice President of Diagnostic Development at Precision for Medicine. He brings more than 20 years of bioanalytical assay experience to the Precision team with expertise in ligand-binding and cell-based assays.  Travis has experience supporting clinical and nonclinical studies for a broad range of indications, with an emphasis on diagnostic assays to evaluate immune responses to gene therapies., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Travis%20Harrison.webp',altText='Travis Harrison',fileId=165893006481}, linkedin=https://www.linkedin.com/in/travis-harrison-phd-6108852/, hs_name=, hs_path=, lastname=Harrison, hs_initial_published_at=1716212769184, hs_created_at=1709645745120, hs_is_edited=false, hs_deleted_at=0, name=Travis, job=, slug=travis-harrison, email=, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Travis Harrison avatar

    Travis Harrison

gene-expression-profiling-of-biopsies_card-thumbnail

Beyond AAV immunogenicity assays, Precision is a full-service CRO with expertise in gene, cell, and novel therapies

Precision’s transformational approach to biomarker and assay development, and clinical trials, ensures comprehensive services and expertise for every gene therapy development challenge, from IND-enabling assays to commercialization.

50 rare disease clinical trials and trials for 100+ orphan projects
12 sample processing locations worldwide
350 IVD and CDx global regulatory submissions and registrations